A huge milestone for Cellen this month - Project Twenty21 has officially launched, led by Professor David Nutt. We are incredibly proud to be a partner for this important project.
After a successful beta test, we will be aiming to enrol 20,000 UK patients over the next 2 years to understand safety and efficacy of Medical Cannabis. As a UK-based, independent company, we are thrilled at Cellen to be continuing our mission of improving the health of people living with chronic conditions! Project Twenty21 will be the largest European observational registry of patients taking prescribed Medical Cannabis.
Medical Cannabis in the UK is still very difficult to access for patients living with chronic conditions, and hopefully this project will help to provide much needed information on this treatment.
If you would like to find out how you can get involved as a patient or clinician, please visit the Drug Science website at https://drugscience.org.uk/project-twenty21/.
For more information please reach out to us at email@example.com